XAIR
Beyond Air, Inc. · Healthcare
Insiders bought $257K of Beyond Air, Inc. in the last 12 months
2 insiders bought on 2 days.
XAIR over the last year
Largest buyers, last 12 months
XAIR after insider buys
3 months after each buy, from the first price a copier could get.
15 buys since 2019 with 3 months of prices.
Every filing
75 insider filings since 2019, newest first
Yi-Chien Lin · 10% owner
Robert Scott Goodman · Chief Executive Officer
Robert Carey · Director
Robert Carey · Director
Steven A. Lisi · CEO and Chair
Robert Carey · Director
Steven A. Lisi · CEO and Chair
Amir Avniel · Chief Business Officer
Steven A. Lisi · CEO and Chair
Robert Carey · Director
Robert Carey · Director
William P Forbes · Director
Steven A. Lisi · CEO and Chair
William P Forbes · Director
Robert Carey · Director
Michael A. Gaul · COO
Steven A. Lisi · CEO and Chair
Robert Carey · Director
Steven A. Lisi · CEO and Chair
Robert Carey · Director
Steven A. Lisi · CEO and Chair
Robert Carey · Director
Amir Avniel · COO and President
Ron Bentsur · Director
Robert Carey · Director
Robert Carey · Director
Robert Carey · Director
Steven A. Lisi · CEO and Chair
Amir Avniel · COO and President
Ron Bentsur · Director
Robert Carey · Director
Robert Carey · Director
Robert Carey · Director
Steven A. Lisi · CEO and Chair
Robert Carey · Director
Ron Bentsur · Director
Robert Carey · Director
Steven A. Lisi · CEO and Chair
Ron Bentsur · Director
Steven A. Lisi · CEO and Chair
Robert Carey · Director
Ron Bentsur · Director
Amir Avniel · COO and President
Ron Bentsur · Director
Amir Avniel · COO and President
Ron Bentsur · Director
Amir Avniel · COO and President
Steven A. Lisi · CEO and Chair
Ron Bentsur · Director
Amir Avniel · COO and President
About Beyond Air, Inc.
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.